showed a trendp = 0.096
A larger randomized, controlled clinical trial in patients with severe COVID-19 treated with IgM/IgA-enriched Ig preparations showed a trend towards a reduced composite deterioration/mortality rate ( p = 0.096) when treatment was started before invasive mechanical ventilation and before respiratory dysfunction and coagulopathy had progressed into advanced stages [ 143 ].